Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
5,278
-7.11%
|
$348,348
$66.37 P/Share
|
|
Oct 31
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55
+0.07%
|
$3,080
$56.01 P/Share
|
|
Sep 30
2024
|
Gregory R Friberg EVP, Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,060
+35.66%
|
-
|
|
Sep 13
2024
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
12,098
-6.14%
|
$1,016,232
$84.9 P/Share
|
|
Aug 13
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
714
-4.71%
|
$64,260
$90.0 P/Share
|
|
Jun 28
2024
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
588
-0.81%
|
$48,216
$82.33 P/Share
|
|
Jun 03
2024
|
Elaine J Heron Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,168
-4.09%
|
$316,768
$76.41 P/Share
|
|
Jun 03
2024
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,047
+4.72%
|
$317,961
$63.1 P/Share
|
|
Jun 03
2024
|
Richard A Meier Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,451
-4.32%
|
$414,276
$76.41 P/Share
|
|
Jun 03
2024
|
Richard A Meier Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,600
+4.97%
|
$415,800
$63.1 P/Share
|
|
May 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.48%
|
$375,000
$75.19 P/Share
|
|
May 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.09%
|
$315,000
$63.1 P/Share
|
|
May 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
40,850
-21.98%
|
$3,022,900
$74.87 P/Share
|
|
May 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,850
+29.63%
|
$2,573,550
$63.1 P/Share
|
|
May 21
2024
|
Richard A Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,080
+5.59%
|
-
|
|
May 21
2024
|
David E I Pyott Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+8.67%
|
-
|
|
May 21
2024
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+18.1%
|
-
|
|
May 21
2024
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+11.82%
|
-
|
|
May 21
2024
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+4.65%
|
-
|
|
May 21
2024
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+12.75%
|
-
|
|
May 21
2024
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+40.62%
|
-
|
|
May 21
2024
|
Athena Countouriotis Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+40.62%
|
-
|
|
May 21
2024
|
Elizabeth M Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+14.51%
|
-
|
|
May 21
2024
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+40.62%
|
-
|
|
May 20
2024
|
Cristin Hubbard EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,390
+34.76%
|
-
|
|
May 20
2024
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,202
-0.25%
|
$92,554
$77.05 P/Share
|
|
May 17
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
993
-6.15%
|
$75,468
$76.97 P/Share
|
|
May 10
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,620,000
$81.14 P/Share
|
|
May 10
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
May 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,620,000
$81.62 P/Share
|
|
May 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
May 03
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,440
-5.65%
|
$364,080
$82.44 P/Share
|
|
May 02
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,850
-3.19%
|
$157,250
$85.01 P/Share
|
|
May 02
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,850
+3.09%
|
$116,550
$63.1 P/Share
|
|
May 02
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.97%
|
$410,000
$82.91 P/Share
|
|
Apr 30
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.15%
|
$20,400
$68.65 P/Share
|
|
Apr 30
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.41%
|
$20,400
$68.65 P/Share
|
|
Apr 30
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
245
+0.31%
|
$16,660
$68.65 P/Share
|
|
Apr 30
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
301
+0.53%
|
$20,468
$68.65 P/Share
|
|
Apr 30
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.42%
|
$20,400
$68.65 P/Share
|
|
Apr 12
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,820,000
$91.26 P/Share
|
|
Apr 12
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
Apr 11
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-4.04%
|
$1,800,000
$90.99 P/Share
|
|
Apr 11
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.88%
|
$1,260,000
$63.1 P/Share
|
|
Apr 10
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,286
-12.4%
|
$205,740
$90.0 P/Share
|
|
Mar 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
24,602
-30.58%
|
$2,164,976
$88.34 P/Share
|
|
Mar 18
2024
|
Dennis Slamon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,510
-23.3%
|
$789,330
$83.81 P/Share
|
|
Mar 18
2024
|
Dennis Slamon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.68%
|
$790,000
$79.7 P/Share
|
|
Mar 18
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-1.98%
|
$30,876
$83.87 P/Share
|
|
Mar 15
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+20.06%
|
-
|